Pilots Between NHS And Pharma Finally Take Off
The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.
You may also be interested in...
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.